Chris Lau
All posts from Chris Lau
Chris Lau in Value Stocks,

Weekend Thoughts: Four Stocks Flying to the Moon

Quarterly reporting continued on August 4, with (1) Activision (ATVI) blowing past estimates…again. Activision earned $0.45 per share ($0.41/sh consensus) and sales of $1.57B ($1.46B estimates).

At a forward P/E of 19, ATVI is not easy profits for bulls but the stock will unlikely fall.

(2) Rackspace (RAX) shot higher on rumors it is once again looking for buyers.

(3) Array Biopharma (ARRY) gave an update on its binimetinib and encorafenib. Novartis (NVS) paid 107.3M in the last year. NEMO trial results are promising.

Per the press release:

“ The median PFS on the binimetinib arm was 2.8 months versus 1.5 months on the dacarbazine arm; hazard ratio (HR) 0.62, [95% CI 0.47-0.80], p<0.001.”


“patients who received binimetinib experienced 5.5 months of median PFS (95% CI, 2.8–7.6), compared with 1.6 months for those receiving treatment with dacarbazine (95% CI, 1.5–2.8).

Though reimbursement revenue clearly drove the share price, commercialization of drugs in the pipeline will drive the stock higher.

Gravity strikes for (4) First Solar (FSLR)

First Solar is a value stock favorite. The company’s 5.74x P/E reflects the market’s disappointment over the lowered outlook. Gross margin expectations are higher. Cash flow guidance is at a lowered range but still within an acceptable level.


Thinking of loading up on Tesla (TSLA)? Don't. The company will have no issue raising share sales or debt, but capex costs keep exceeding revenue. Look at Trina (TSL) instead. It is a long idea here and is still below the buy-out price.